Ernexa Therapeutics Inc. (ERNA) Form 8-K — Sep 16, 2026

$ERNAForm 8-KItems 5.02Filed Sep 16, 2026, 4:50 PM ET0001493152-26-042934Original filing

Ernexa Therapeutics Inc. (Nasdaq: ERNA) disclosed in an 8-K filed September 16, 2026 that its board appointed Robert J. Spiegel, M.D. as a director, effective September 14, 2026.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.